Editorial: re-thinking cardiovascular risk factors in NAFLD with advanced fibrosis? Authors' reply

被引：0
|
作者：
Henson, Jacqueline B. [1 ]
Corey, Kathleen E. [1 ]
机构：
[1] Massachusetts Gen Hosp, Dept Med, Div Gastroenterol, Ctr Liver, Boston, MA 02114 USA
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2020年 / 51卷 / 10期
关键词：
D O I：
10.1111/apt.15696
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：988 / 989
页数：2
相关论文
共 50 条
  • [31] LOW RATE OF EXTENSIVE FIBROSIS IN YOUNG HCV PATIENTS: RE-THINKING SIMPLIFIED TREATMENT ALGORITHMS
    Ramji, Alnoor
    Tam, Edward V.
    MacIsaac, Julia
    Widmer, Nadia
    Wallach, Jean-Philippe
    Lewendon, Shayla
    Farivar, Jeanette Feizi
    Ko, Hin Hin
    [J]. HEPATOLOGY, 2022, 76 : S384 - S385
  • [32] Editorial: stepwise risk stratification for both F3 and F4 in NAFLD patients-authors' reply
    Labenz, Christian
    Schattenberg, Joern M.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (11-12) : 1318 - 1319
  • [33] Re-Thinking Online Offenders' SKRAM: Individual Traits and Situational Motivations as Additional Risk Factors for Predicting Cyber Attacks
    Maimon, David
    Hinton, Steve
    Babko-Malaya, Olga
    Cathey, Rebecca
    [J]. 2017 IEEE 15TH INTL CONF ON DEPENDABLE, AUTONOMIC AND SECURE COMPUTING, 15TH INTL CONF ON PERVASIVE INTELLIGENCE AND COMPUTING, 3RD INTL CONF ON BIG DATA INTELLIGENCE AND COMPUTING AND CYBER SCIENCE AND TECHNOLOGY CONGRESS(DASC/PICOM/DATACOM/CYBERSCI, 2017, : 232 - 238
  • [34] Editorial: "being normal weight each day keeps NAFLD and fibrosis away"-the importance of reducing cumulative exposure to overweight. Authors' reply
    Ajmera, Veeral
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (10) : 1168 - 1169
  • [35] Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV
    Cervo, Adriana
    Sebastiani, Giada
    Milic, Jovana
    Krahn, Thomas
    Mazzola, Sergio
    Petta, Salvatore
    Cascio, Antonio
    Guaraldi, Giovanni
    Mazzola, Giovanni
    [J]. HIV MEDICINE, 2022, 23 (08) : 911 - 921
  • [36] Editorial: Will MRI-PDFF become the new standard for steatosis assessment in NAFLD? Authors' reply
    Huang, Daniel Q.
    Loomba, Rohit
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (03) : 366 - 367
  • [37] Re-thinking How We Use Prostate Health Index for African American Men Reply
    Morris, Kostantinos E.
    Kotamarti, Srinath
    Polascik, Thomas J.
    Moul, Judd W.
    [J]. UROLOGY, 2023, 175 : 149 - 150
  • [38] Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk
    Delgado, Graciela E.
    Kleber, Marcus E.
    Moissl, Angela P.
    Yazdani, Babak
    Kusnik, Alexander
    Ebert, Matthias P.
    Maerz, Winfried
    Kraemer, Bernhard K.
    Lammert, Alexander
    Teufel, Andreas
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2021, 321 (03): : G252 - G261
  • [39] CARDIOVASCULAR RISK-FACTORS - REPLY
    JONES, A
    [J]. BRITISH MEDICAL JOURNAL, 1988, 297 (6647): : 558 - 558
  • [40] Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD?
    Hagstrom, Hannes
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (11) : 1204 - 1205
12345